The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
CJ,
While the share price action has been poor, and to date, Huw has not demonstrated strength as a CEO, the fundamentals of the company remain strong. The science is more promising now than it ever has been. Progress has been slower than hoped and the lack of director buying is disappointing, however, that former is the nature of the industry.
Be under no illusions, most investors are well aware that Evgen remains a high-risk investment, any clinical stage biotech is. However, it is in a far better position than many of its peers. Phara is a long game, and anyone that has bought in within the last few years will be handsomely rewarded should SFX-01 be all we hope it is and what the latest research suggests.
Multiple times I've seen references that Kight will be dissatisfied and wishing he had never bought his shares. To this point I would say that none of us knows Kight personally and so cannot suggest how he may or may not feel about his Evgen investment. However, to date he has not sold, and this suggests that he is currently still happy to hold. The fundamentals and science have not deteriorated since his investment, and it would be irrational to believe he bought such a large quantity purely on hope and shortsightedness, without doing due diligence first. - I highly doubt he would have bought with the hope of hitting a 10-bag within a year - unlike most retail investors who ‘invest’ in Aim companies.
Evgen has enough cash to last until the end of 2024, before including any payments from Stalicla that may be received which would extend this into 2025 and beyond. We are trading just above cash value despite the fact that we have a deal worth up to $160M in millstone payments alone. Point me to another biotech company that is this undervalued on a fundamental basis, I highly doubt you can.
You seem to be highly emotional, making childish remarks on this board, while demanding apologies. You lost a small sum when you sold out, and while selling for a loss is never nice irrespective of the value, you are coming across as very bitter. You don't take aim at the fundamentals of the company, have previously based your judgement on the capabilities of SFX-01 on anecdotal evidence instead of listening to what the actual professionals have stated, or the research presented by the company and you seem to be using unjustified fear tactics to attempt to deramp the share.
At the moment I feel as though I am in a taxi being taken from from London to Bristol via edinburgh because the Driver likes driving and he is on the meter.
This is what annoys my about the BoD. They seem transfixed by the science.
Science can have many uses and benefits but a listed company exists for one reason only - to make money for shareholders.
Huw needs to stop focusing on being a doctor and focus on being a CEO, the science is just a means to an end.
I was looking over past comments here to see who was critical of mine and Alf’s comments here over recent months. It struck me that some posters were critical of my opinions because they said that EVG’s mission to help treat cancers and other illnesses, disorders and diseases meant it was wrong to be critical.
Can I ask, have I made a mistake - did people here buy EVG shares as they wanted to help fund a company that are doing good rather than it being an investment? That’s really commendable of people if that is the case, that’s like donating thousands to charity and I really am genuinely sorry for being critical of you if you bought shares as a charitable gesture. It’s no wonder we clashed as I’ll be honest, I invested hoping to make money.
It will be Stalicla applying for the IND, but yes I would assume the full report of the Phase1b was a significant part of the information needed for the application. The proposed design of the trial will be another major part which as of the 31/10 full year report was still being thrashed out.
· Discussions continue with partner Stalicla SA on optimal design of the Phase 2 study in autism spectrum disorder.
The good news is based on other companies experiences the FDA appear to be moving quite quickly these days so once the application is in things should move at a good pace. Better to get it right first time as well than rush it and get a clinical hold.
Evgen arent submitting the application .
Stalicla are submitting it.
They required the data from evgen for their application but other than that it is out of evgens hands.
I suppose my point, which is more of a question is when will Evgen be in a position to apply for an FDA IND ?
Could the 'Final Report from Phase 1b PK/PD study' RNS'd in August have been the catalyst for application ?
Final Clinical Study Report from Phase 1b PK/PD study of new SFX-01 tablet formulation approved
New formulation of SFX-01 performs as designed, delivers meaningful levels of drug and metabolites, is safe and well tolerated
Results to be shared with Evgen Partner, Stalicla in support of regulatory submissions for Phase 2 studies in Autism Spectrum Disorder.
Not sure what point you’re trying to make DSFLAT?
One thing i am sure about is the timelines including when the IND application is filed with the FDA are under the control of Stalicla, and Evgen directors are unlikely to have come up with them themselves off the top of their heads?
What do investors think happened with this statement:
10 Oct 2022 07:00
RNS Number : 2587C
Evgen Pharma PLC
Key financial elements of the transaction
· $0.5m upfront, $0.5m on completion of the, already fully financed, Evgen-sponsored human volunteer Phase 1 study (anticipated during Q2 2023). Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double-digit range in all scenarios, including on-licensing by Stalicla and use of SFX-01 in further licensed indications.
I suspect Evgen BOD may have misunderstood the 'deal' requirements for the '$5m on grant of IND by the FDA (anticipated in late 2023)'...
https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
I'd be interested to hear what other investors think may have led to this statement via RNS last October.
Inv€$tival Showcase is your Ultimate Biotech, Healthtech and Medtech Networking & Pitching Event in London.
Hugh & Helen must be able to rustle some new investor interest this week...?
https://www.lsxleaders.com/investival-showcase
Nolupus
I agree they should be presenting what could be ground breaking drug discoveries Unfortunately the SP for most on this BB is more of a concern hence my sarcasm
Huw went to California in the summer to network and tout for business but clearly nothing came if it.
It's good to see that Evg are presenting At major conferences . These are not for Joe Soap shareholders but they would not be participating if they had nothing to Say, is my opinion but everyone to their own...
Thanks for the invite Huw to San Fran to meet up However down on my luck atm share portfolio and equity not looking good Anyway enjoy the party Perhaps next year if you remember
Adios
Joe Soap
Yes radar it is. Everything takes forever here, it’s just not worth being invested here as it takes years to materialise, that’s if this does ever become a success. If the Stalicla deal is successful then surely Stalicla will buy EVG out for peanuts to avoid having to pay these large milestone payments.
Directors still not buying shares. No concrete update on how much and when next Stalicla payments are due. Juvenesense pulled out. It’s not in a good place right now.
In one word a mess (and a sorry one at that)
Keeping my eye on the Ball and not listening to the BULL.... Or should i Say the Bear.... ?
Everyone to their own :-)
Good point Alf. Why is there only positive upbeat posters here when the share price has been in constant decline over recent years? 4 and a half years ago the share price was 23p per share and is now 1.8p. If you bought £10k worth of shares 4 and a half years ago, your investment now would be worth £782. Great investing. Isn’t investing supposed to be about making money not losing it all?
With the share price this low I would expect a lot more negative comments from disgruntled investors. Seem to be some die hards on here where the bods can do no wrong which is very confusing. Are some of the most ultra positive posts from the bods themselves. With this lot anything is possible.
Trickymatters, don’t get smart sunshine, it doesn’t suit you.
You’re talking stupid, I can’t believe you have no problem with the board never buying shares, that alone shows you what they think of this as an investment because no one knows the business potential more than them. You seem to think you know more than the board which is very interesting.
I would consider buying back in here but only if there was significant big news and some major injection of money was to happen. I don’t expect someone like you to understand that though. You are happy to let your investment dwindle towards nothing and clapping like a performing seal at Huw and the board for delivering no value.
CJ, they aren't making money if they aren't selling shares. Do you know how this works?😆 Significant results are not due yet. I guess that's why the sp is falling. No-one owes you an apology. I will buy some more when I think we're closer to the Staclia phase 2 trial for autism. It will be a different story then.
I suspect you are hanging around because you want a lower buy in price. Everyone has seen it all before mate. If you aren't in and you know nothing, don't post. Don't think anyone is bothered by your pearls of wisdom. All you're doing is making up a story. If you have a credible criticism of the science then maybe share it..
Tricky, I’m no longer invested but I’m still very interested in this share. I’m curious to know if I made the right decision in selling out at 2.55p. I’m curious as to how this pans out. I also feel I have a good idea about this share so could potentially make money here if things change for the better.
I agree Alf, in the last QnA, Huw said share price performance was really important to them. If it was that important then buy in, give more helpful info on when income from Stalicla is going to be received so investors know that funds are not going to run out.
One thing I can guarantee here is that Huw and the other board members will be laughing their behinds off seeing mugs investing here. I bet they go around saying “I bought a new car at the weekend, all courtesy of those mugs Trickymatters and DSFiat.
Have you also noticed how quiet K3VMC has been in recent months. He was giving it large that we were talking nonsense in saying this was looking like a bad investment. Kev, if you’re reading, I do need an apology from you.
Warn others in relation to the title of this post
All, you told us all you've sold. So what on earth are you doing here?
Well the market is clearly seeing through all the bods Bullsxxt, such optimism but that doesn't stretch to them buying in. Please don't invest on what the new CFO was saying about adding to shareholder value. I would have expected them to at least acknowledge the dire share price performance over the last 9 months, but no it was the usual promising the earth drivel to entice more unsuspecting punters. Aim company and board at its worst.